News

Published on 25 Apr 2024 on Benzinga via Yahoo Finance

AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance

Article preview image

AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance

Thursday, AstraZeneca Plc (NASDAQ:AZN) reported first-quarter sales of $12.68 billion, up 17% year over year (+19% at constant currency), slightly below the consensus of $11.83 billion.

This was fueled by an 18% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines.

Read the rest of the article
LSE.AZN price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19:...

Tesla CEO Elon Musk does not seem to agree with Republicans at least on one thing. On Wednesday, ...

Benzinga 9 May 2024
GSK expands collaboration with BioVersys on tuberculosis asset alpibectir

GSK expands collaboration with BioVersys AG and invests in their latest funding round, propelling...

Seeking Alpha 7 May 2024
The Zacks Analyst Blog Highlights AstraZeneca, Qualcomm, FedEx, American International and Baker...

For Immediate Release Chicago, IL – May 6, 2024 – Zacks.com announces the list of stocks featured...

Zacks via Yahoo Finance 6 May 2024
Vanguard Health Care Fund's Strategic Moves in Q1 2024: A Focus on Pfizer Inc

Insight into the Fund's Latest Investment Decisions and Stock Adjustments Vanguard Health Care Fu...

GuruFocus.com via Yahoo Finance 3 May 2024
Top Analyst Reports for AstraZeneca, QUALCOMM & FedEx

Thursday, May 3, 2024The Zacks Research Daily presents the best research output of our analyst te...

Zacks via Yahoo Finance 3 May 2024
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

(NASDAQ: ONCY) (TSX: ONC), Celcuity Inc. (NASDAQ: CELC), Olema Pharmaceuticals, Inc. (NASDAQ: OLM...

WTNH-TV New Haven 3 May 2024
Obesity drug rivals aim to unseat Zepbound, Ozempic - Indianapolis Business Journal

Insatiable demand for weight-loss drugs has made the market so feverish that any positive mention...

Indianapolis Business Journal 3 May 2024
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

(NASDAQ: ONCY) (TSX: ONC), Celcuity Inc. (NASDAQ: CELC), Olema Pharmaceuticals, Inc. (NASDAQ: OLM...

FOX 4 Kansas City 3 May 2024
Novo Slides as Amgen Fuels Obesity Drug Competition Fears

(Bloomberg) -- Novo Nordisk A/S shares fell as a US rival’s comments on an experimental obesity d...

Bloomberg via Yahoo Finance 3 May 2024
AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript

AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript April 25, 2024 AstraZeneca PLC miss...

Insider Monkey via Yahoo Finance 30 Apr 2024

Copyright Statfolio @ 2024

Social Accounts